GlassScriptPhysician profile
Seetha R Murukutla
NPI 1851300271
$19,386.17
in general payments reported to CMS, 2019-2025
63 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,781 · 2020: $2,399 · 2021: $2,877 · 2022: $6,348 · 2023: $3,057 · 2024: $463 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,762 · Education: $767 · Travel and Lodging: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,762.21 |
| Education | $766.76 |
| Travel and Lodging | $451.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,730.24 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Astrazeneca Pharmaceuticals LP | $1,713.35 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Beigene USA, INC. | $1,125.00 | 2022 | |
| Merck Sharp & Dohme LLC | $1,110.65 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $1,077.34 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Seagen INC. | $936.05 | 2019-2025 | Padcev, Adcetris, Tukysa |
| Genzyme Corporation | $910.90 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $904.94 | 2019-2023 | |
| US Oncology Corporate, INC. | $841.88 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $821.29 | 2019-2022 | |
| Pfizer INC. | $701.40 | 2019-2023 | |
| Adaptive Biotechnologies Corporation | $693.57 | 2021-2025 | Clonoseq |
| Janssen Biotech, INC. | $581.84 | 2019-2025 | Darzalex, Erleada |
| Incyte Corporation | $540.10 | 2019-2023 | Jakafi |
| Genentech USA, INC. | $495.73 | 2019-2023 | Venclexta |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seetha Murukutla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.